Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation
Open Access
- 22 September 2020
- journal article
- editorial
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 141 (4), 930-933
- https://doi.org/10.1016/j.jid.2020.07.036
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 10 references indexed in Scilit:
- Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric ModelsCPT: Pharmacometrics & Systems Pharmacology, 2019
- Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic ModelsClinical Cancer Research, 2019
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialEuropean Journal of Cancer, 2017
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyBMC Cancer, 2017
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trialThe Lancet Oncology, 2017
- Managing adverse events associated with vismodegib in the treatment of basal cell carcinomaFuture Oncology, 2017
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell CarcinomaThe Oncologist, 2016
- Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.Journal of Clinical Oncology, 2015
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009